Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.58 |
| ▸ | NQO2 | P16083 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234563 | 1.00 | NFE2L2 (0.58) | NFE2L2NQO2CTSLTUBB4ATUBB | |
| SCHEMBL3236239 | 0.93 | CYP1A1 (0.49) | NFE2L2NQO2TUBB4ATUBBTUBA3C | |
| SCHEMBL3236248 | 0.93 | CYP1A1 (0.49) | NFE2L2NQO2TUBB4ATUBBTUBA3C | |
| SCHEMBL15673888 | 0.88 | TNFRSF1A (0.42) | NFE2L2NQO2ALOX5PTGS2 | |
| SCHEMBL3234318 | 0.86 | CYP19A1 (0.50) | NQO2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3238576 | 0.86 | NFE2L2 (0.56) | NFE2L2NQO2TUBB4ATUBBTUBA3C | |
| SCHEMBL3234312 | 0.86 | CYP19A1 (0.50) | NQO2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5871380 | 0.86 | APP (0.43) | NFE2L2NQO2TUBB4ATUBBTUBA3C | |
| SCHEMBL1195422 | 0.86 | MAOA (0.52) | NQO2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1194745 | 0.86 | NFE2L2 (0.56) | NFE2L2NQO2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | claimed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-11-18 | — | — | US | claimed |
| US-6762207-B1 | TARGETING RECEPTOR TYROSINE KINASES; SELECTIVE TUMOR CELL APOPTOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-13 | — | — | US | claimed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | claimed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | claimed |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2769719-A1 | Formulations of radioprotective alpha, beta unsaturated aryl sulfones | Onconova Therapeutics, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2046343-B1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-1909775-B1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6787667-B2 | POLYSULFONSTYRENE POLYMER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-09-07 | — | — | US | disclosed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| US-6762207-B1 | TARGETING RECEPTOR TYROSINE KINASES; SELECTIVE TUMOR CELL APOPTOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-13 | — | — | US | disclosed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | NFE2L2 35/4885NQO2 816/4885CTSL 2060/4885 |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | SULT1E1, CCNE1, RPS3A | NFE2L2 640/4885NQO2 697/4885CTSL 3369/4885 |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | DEGS1, ARSA, ABCE1 | NFE2L2 147/4885NQO2 2602/4885CTSL 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.